The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
Open accessAbstract
Deregulation of the phosphoinositide 3-kinase (PI3K) pathway has been implicated in numerous pathologies like cancer, diabetes, thrombosis, rheumatoid arthritis and asthma. Recently, small molecule and ATP-competitive PI3K inhibitors with a wide range of selectivities have entered clinical development. In order to understand mechanisms underlying isoform selectivity of these inhibitors, we developed a novel expression strategy that enabled us to determine the first crystal structure of the catalytic subunit of the class IA PI3K p110δ. Structures of this enzyme in complex with a broad panel of isoform- and pan-selective class I PI3K inhibitors reveal that selectivity towards p110δ can be achieved by exploiting its conformational flexibility and the sequence diversity of active-site residues that do not contact ATP. We have used these observations to rationalize and synthesize highly selective inhibitors for p110δ with greatly improved potencies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Synthesis and Function of 3-Phosphorylated Inositol Lipids
Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., Woscholski, R., Parker, P. J., & Waterfield, M. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.535 · Cited by 1,535
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., & Williams, R. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00089-4 · Cited by 1,197
Self-citationA Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Self-citationArcaro, A., & Wymann, M. P. (1993) · Biochemical Journal · doi:10.1042/bj2960297 · Cited by 1,140
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Signaling by Distinct Classes of Phosphoinositide 3-Kinases
Vanhaesebroeck, B., & Waterfield, M. D. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4701 · Cited by 853
Kornev, A. P., Haste, N. M., Taylor, S. S., & Ten Eyck, L. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607656103 · Cited by 762
Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis
Camps, M., Rückle, T., Ji, H., Ardissone, V., Rintelen, F., Shaw, J., Ferrandi, C., Chabert, C., Gillieron, C., Françon, B., et al. (2005) · Nature Medicine · doi:10.1038/nm1284 · Cited by 750
Self-citationFolkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800295d · Cited by 741
Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ
Pacold, M. E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C. T., Walker, E. H., Hawkins, P. T., Stephens, L., Eccleston, J. F., & Williams, R. L. (2000) · Cell · doi:10.1016/s0092-8674(00)00196-3 · Cited by 602
Self-citationClass I PI3K in oncogenic cellular transformation
Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 594
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
Self-citationPI 3-kinase p110β: a new target for antithrombotic therapy
Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide, S. M., Yuan, Y., et al. (2005) · Nature Medicine · doi:10.1038/nm1232 · Cited by 580
The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations
Huang, C.-H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 560
Structural insights into phosphoinositide 3-kinase catalysis and signalling
Walker, E. H., Perisic, O., Ried, C., Stephens, L., & Williams, R. L. (1999) · Nature · doi:10.1038/46319 · Cited by 494
Self-citationTargeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., & Knight, Z. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.117 · Cited by 440
Self-citationMechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit
Miled, N., Yan, Y., Hon, W.-C., Perisic, O., Zvelebil, M., Inbar, Y., Schneidman-Duhovny, D., Wolfson, H. J., Backer, J. M., & Williams, R. L. (2007) · Science · doi:10.1126/science.1135394 · Cited by 410
Self-citationPI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?
Rommel, C., Camps, M., & Ji, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2036 · Cited by 398
Self-citationAntitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor
Yaguchi, S.-I., Fukui, Y., Koshimizu, I., Yoshimi, H., Matsuno, T., Gouda, H., Hirono, S., Yamazaki, K., & Yamori, T. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj133 · Cited by 387
p110δ, a novel phosphoinositide 3-kinase in leukocytes
Vanhaesebroeck, B., Welham, M. J., Kotani, K., Stein, R., Warne, P. H., Zvelebil, M. J., Higashi, K., Volinia, S., Downward, J., & Waterfield, M. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4330 · Cited by 376
Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement
Sadhu, C., Masinovsky, B., Dick, K., Sowell, C. G., & Staunton, D. E. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.5.2647 · Cited by 365
Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 352
Ihle, N. T., Williams, R., Chow, S., Chew, W., Berggren, M. I., Paine-Murrieta, G., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.763.3.7 · Cited by 313
Self-citationA frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane
Mandelker, D., Gabelli, S. B., Schmidt-Kittler, O., Zhu, J., Cheong, I., Huang, C.-H., Kinzler, K. W., Vogelstein, B., & Amzel, L. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908444106 · Cited by 293
Garlich, J. R., De, P., Dey, N., Su, J. D., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G. B., Kundra, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0669 · Cited by 279
Raynaud, F. I., Eccles, S. A., Patel, S., Alix, S., Box, G., Chuckowree, I., Folkes, A., Gowan, S., De Haven Brandon, A., Di Stefano, F., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1200 · Cited by 271
Kang, S., Denley, A., Vanhaesebroeck, B., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510772103 · Cited by 267
Chantry, D., Vojtek, A., Kashishian, A., Holtzman, D. A., Wood, C., Gray, P. W., Cooper, J. A., & Hoekstra, M. F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19236 · Cited by 253
Sujobert, P. (2005) · Blood · doi:10.1182/blood-2004-08-3225 · Cited by 245
Using structure to define the function of phosphoinositide 3‐kinase family members
Domin, J., & Waterfield, M. D. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00617-0 · Cited by 233
Hayakawa, M., Kaizawa, H., Moritomo, H., Koizumi, T., Ohishi, T., Yamano, M., Okada, M., Ohta, M., Tsukamoto, S., Raynaud, F. I., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.032 · Cited by 162
Chemically targeting the PI3K family
Knight, Z. A., & Shokat, K. M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350245 · Cited by 134
Self-citationWilliams, O., Houseman, B. T., Kunkel, E. J., Aizenstein, B., Hoffman, R., Knight, Z. A., & Shokat, K. M. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.01.010 · Cited by 86
Self-citationForm and flexibility in phosphoinositide 3-kinases
Williams, R., Berndt, A., Miller, S., Hon, W., & Zhang, X. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370615 · Cited by 75
Self-citationTakeda, M., Ito, W., Tanabe, M., Ueki, S., Kato, H., Kihara, J., Tanigai, T., Chiba, T., Yamaguchi, K., Kayaba, H., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.11.047 · Cited by 72
Yu, K., Lucas, J., Zhu, T., Zask, A., Gaydos, C., Toral‐Barza, L., Gu, J., Li, F., Chaudhary, I., Cai, P., et al. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.5.1660 · Cited by 66
Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
Ameriks, M. K., & Venable, J. D. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789044434 · Cited by 58
Hickey, F. B., & Cotter, T. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511173200 · Cited by 55
Sundstrom, T. J., Anderson, A. C., & Wright, D. L. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b819067b · Cited by 47
Phosphoinositide 3‐kinase δ inhibitor as a novel therapeutic agent in asthma
Park, S. J., Min, K. H., & Lee, Y. C. (2008) · Respirology · doi:10.1111/j.1440-1843.2008.01369.x · Cited by 31
Research works printed but not linked: 1
- Ghigo, A. & Hirsch, E. Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential. Recent Pat. Inflamm. Allergy Drug Discov. 2, 1–10 (2008). · doi:10.2174/187221308783399270
Cited by
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Self-citationPhosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation
Balla, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00028.2012 · Cited by 1,638
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
PI3K signalling: the path to discovery and understanding
Vanhaesebroeck, B., Stephens, L., & Hawkins, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3290 · Cited by 987
Lucas, C. L., Kuehn, H. S., Zhao, F., Niemela, J. E., Deenick, E. K., Palendira, U., Avery, D. T., Moens, L., Cannons, J. L., Biancalana, M., et al. (2014) · Nature Immunology · doi:10.1038/ni.2771 · Cited by 673
Metadata
- Authors
- Berndt, A., Miller, S., Williams, O., Le, D. D., Houseman, B. T., Pacold, J. I., Gorrec, F., Hon, W.-C., Ren, P., Liu, Y., Rommel, C., Gaillard, P., Rückle, T., Schwarz, M. K., Shokat, K. M., Shaw, J. P., & Williams, R. L.
- Venue
- Nature Chemical Biology
- Published
- 2010-01-10
- Volume
- 6
- Issue
- 2
- Pages
- 117-124
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2127355894
- Cited by
- 292
- References
- 46
- FWCI
- 10.04
- Type
- journal article
- Language
- en
- Update notices
- erratum (2010-03-01)
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.